Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for temporarily suspending a workflow associated with a work item. The system is configured to establish a communicable link with a queue to retrieve a first work item. The system is configured to receive a notification from a first device, where the notification comprises a second work item. The system temporarily suspends the first work item and the work flow associated with the first work item, in response to receiving the second work item from the first device. Once the system determines execution of a user action associated with the second work item, it restores the suspended first work item and the one or more suspended sessions associated with the first work item.

Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for temporarily suspending a workflow associated with a work item. The system is configured to establish a communicable link with a queue to retrieve a first work item. The system is configured to receive a notification from a first device, where the notification comprises a second work item. The system temporarily suspends the first work item and the work flow associated with the first work item, in response to receiving the second work item from the first device. Once the system determines execution of a user action associated with the second work item, it restores the suspended first work item and the one or more suspended sessions associated with the first work item.

Abstract: Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.

Abstract: Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.

Abstract: Methods are provided for generating immune responses utilizing alphavirus-based vector systems.

Abstract: The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell.

Abstract: Methods are provided for generating immune responses utilizing alphavirus-based vector systems.

Abstract: The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell.

Abstract: This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. Compounds of the present invention inhibit HCV infection of cells susceptible to HCV infection.